<?xml version="1.0" encoding="UTF-8"?>
<ref id="B124-biomedicines-08-00060">
 <label>124.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Senzer</surname>
    <given-names>N.N.</given-names>
   </name>
   <name>
    <surname>Kaufman</surname>
    <given-names>H.L.</given-names>
   </name>
   <name>
    <surname>Amatruda</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Nemunaitis</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Reid</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Daniels</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Gonzalez</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Glaspy</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Whitman</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Harrington</surname>
    <given-names>K.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorâ€“encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma</article-title>
  <source>J. Clin. Oncol.</source>
  <year>2009</year>
  <volume>27</volume>
  <fpage>5763</fpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2009.24.3675</pub-id>
  <pub-id pub-id-type="pmid">19884534</pub-id>
 </element-citation>
</ref>
